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337 Abstract
38
39 The dissolution of inhaled drug particles in the lungs is a challenge to model using biorelevant 
40 methods in terms of: (i) collecting a respirable emitted aerosol fraction and dose, (ii) presenting 
41 this to a small volume of medium that is representative of lung lining fluid, and (iii) measuring 
42 the low concentrations of drug released.  We report developments in methodology for each of 
43 these steps and utilise mechanistic in silico modelling to evaluate the in vitro dissolution 
44 profiles in the context of plasma concentration-time profiles.  The PreciseInhale® aerosol 
45 delivery system was used to deliver Flixotide aerosol particles to DissolvIt® apparatus for 
46 measurement of dissolution.  Different media were used in the DissolvIt chamber to investigate 
47 their effect on dissolution profiles, these were: (i) 1.5% polyethylene oxide with 0.4% L-
48 alphaphosphatidyl choline, (ii) Survanta®, and (iii) a synthetic simulated lung lining fluid (SLF) 
49 based on human lung fluid composition.  For fluticasone proprionate (FP) quantification, solid 
50 phase extraction was used for sample preparation with LC-MS-MS analysis to provide an assay 
51 which was fit for purpose with a limit of quantification for FP of 312 pg/mL.  FP concentration-
52 time profiles in the flow-past perfusate were similar irrespective of the medium used in the 
53 DissolvIt chamber (~0.04-0.07%/min), but these were significantly lower than transfer of drug 
54 from air-to-perfusate in isolated perfused lungs (0.12%/min).  This difference was attributed to 
55 the DissolvIt system representing slower dissolution in the central region of the lungs (which 
56 feature non-sink conditions) compared to the peripheral regions which are represented in the 
57 isolated lung preparation.  Pharmacokinetic parameters (Cmax, Tmax and AUC0-∞) were 
58 estimated from the profiles for dissolution in the different lung fluid simulants and were 
59 predicted by the simulation within 2-fold of the values reported for inhaled FP (1000 µg dose) 
60 administered via Flixotide Evohaler® 250 μg strength inhaler in man.  In conclusion, we report 
61 methods for performing biorelevant dissolution studies for orally inhaled products and 
62 illustrate how they can provide inputs parameters for physiologically based pharmacokinetic 
63 (PBPK) modelling of inhaled medicines. 
64
65
66 Keywords
67 Flixotide Evohaler, Fluticasone, PreciseInhale, isolated perfused lungs, simulated lung fluid, 
68 Survanta®.
Page 3 of 31
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
470 1. Introduction
71 In vitro dissolution testing is well established for enteral solid dosage forms for quality control 
72 purposes, for comparing products under drug classification frameworks and for predicting drug 
73 pharmacokinetics in vivo[1,2,3,4]. The therapeutic effect of an inhaled particulate aerosol is only 
74 realised after drug release into solution, thus investigating the dissolution of solid particle 
75 aerosol dosage forms has attracted interest [5-8].  Dissolution testing for orally inhaled products 
76 (OIP) is currently a ‘hot topic’ with research groups adapting a panoply of adaptations of 
77 pharmacopoeial apparatus for aerosol collection and dissolution to function as in vitro tests for 
78 discerning the quality attributes of inhaled medicines.  The latest developments in oral 
79 biopharmaceutics demonstrate convincingly that biorelevant methods are important if 
80 dissolution testing is to be used as an in vivo predictive tool and realise its full potential in a 
81 regulatory context and to predict clinically-relevant performance [3,4].
82 The complexity of biorelevant dissolution for inhaled products derives from the need to capture 
83 representative aerosol particles in a dispersed manner that reflects their deposition in the lungs, 
84 present the particles to low volumes of lung fluid-like dissolution medium and measure reliably 
85 the low mass of drug delivered by aerosol medicines.  Of the systems reported to date[5-11], 
86 none accommodates all these features.  The disparate OIP dissolution methods that have been 
87 studied tend to be non-integrated and utilise large volumes of dissolution medium, which 
88 precludes the use of a dissolution medium that represents human lung lining fluid [12,13]. For 
89 some studies of poorly soluble drugs, the medium has been supplemented by addition of protein 
90 or phospholipid components, e.g. surfactants such as DPPC [6,14] or lung surfactant preparations 
91 such as Survanta® [15]. However, biorelevant media are either expensive or difficult to prepare, 
92 and often represent only the surfactant component of distal respiratory tract lining fluid, with 
93 the highly abundant proteins absent.
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594 Recently, an integrated apparatus has been developed by Inhalation Sciences for depositing 
95 aerosols to a flow past dissolution cell [16], comprising the PreciseInhale® and DissolvIt® 
96 systems, respectively.  The PreciseInhale can deliver carefully controlled doses of aerosols 
97 from powder inhalers or pressurised metered dose inhalers to the DissolvIt system, in which 
98 particle dissolution can be followed by simultaneous observation of aerosol particles using 
99 microscopy and measurement of dissolved drug transferred to a flow-past perfusate.  Although 
100 DissolvIt addresses various limitation of dissolution systems used for OIP, the dissolution 
101 vessel contains 5.7 µl of a polyethylene oxide (PEO) gel as the dissolution matrix rather than 
102 a biorelevant medium.  Due to the novelty of the system, there is little reported data on the 
103 performance of the system in predicting dissolution[16, 17].
104 To study clinically-relevant scenarios, dissolution studies to date have focused on the 
105 dissolution of poorly soluble inhaled drugs, in particular fluticasone proprionate (FP) [10,11,18].  
106 Delivery of FP to the DissolvIt with different biorelevant media in the chamber permits 
107 comparison to FP dissolution-absorption profiles in other systems, e.g. isolated perfused lungs 
108 (IPL).  To perform these experiments requires accurate quantification of sub-micromolar 
109 concentrations of FP using a sensitive assay and an efficient extraction method[19,20].  Liquid-
110 chromatography with tandem mass spectrometric detection (LC-MS/MS) provides selective 
111 and sensitive analysis of glucocorticoids in biological fluids[21-23]. However, poor repeatability 
112 using reported methods[21-23] required development of a new solid phase extraction (SPE) 
113 method, which was reliable, quick and required minimal sample preparation and solvent use. 
114 The value of in vitro systems is in providing decision-making data, e.g. dissolution 
115 measurements for predicting and modelling impacts on drug pharmacokinetics in the early 
116 stages of the drug development process.  Such data can expedite drug development and prevent 
117 unexpected toxico-kinetics and ultimately avoid costly end-stage failures[24].  Reliable 
118 predictive models for pharmacokinetics depend on selecting appropriate mathematical 
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6119 approaches and more current studies tend to utilise in silico techniques [25-27].  For modelling 
120 dissolution, Backman et al have described how mechanistic models may aid in obtaining a 
121 better understanding of dissolution which can be used to predict systemic exposure (AUC) and 
122 hence its influence on drug therapeutic effect [28].  For this study, a mechanistic model was 
123 developed to evaluate the dissolution data derived from the biorelevant approach using the 
124 DissolvIt system.
125 In summary, the aim of the present study was to develop a biorelevant dissolution method 
126 by utilising simulated lung fluid in the DissolvIt system.  To measure the dissolution of FP, a 
127 LC-MS/MS method was validated for measurement of low drug concentrations.  The effect of 
128 dissolution medium on FP aerosol particle dissolution was investigated using three different 
129 media: (i) 1.5% polyethylene oxide + 0.4% L-alphaphosphatidyl choline, (ii) Survanta® and 
130 (iii) a synthetic simulated lung lining fluid (SLF), synthesised based on human lung fluid 
131 composition[29,30].  Finally, an in-silico model based on the method of Boger et al[31] was 
132 adapted to explore the impact of the dissolution rates derived on pharmacokinetics.
133
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7134 2. Experimental Section
135 2.1 Materials
136 Flixotide® 50 µg Evohaler (GSK).  Polyethylene oxide (PEO) and L-alphaphosphatidyl choline 
137 were supplied by Sigma Aldrich Limited (Dorset, UK) whereas Survanta® was obtained from 
138 Abbvie Ltd (Berkshire, UK).  The chemicals required for the production of SLF and the 
139 preparation of SLF were carried out according to a recently published method[30].  For solid 
140 phase extraction validation, the chemicals included were micronized FP (USP grade, purity 
141 98%) supplied by LGM Pharma Inc (Boca Raton, USA), pentadeuterated FP (FP-d5; USP 
142 grade, purity 97%) by Insight Biotechnology Limited (Wembley, UK) and rabbit serum, 
143 purchased from Sigma-Aldrich Company Limited (Dorset, UK).  Chemicals needed for the 
144 extraction procedure were zinc sulphate powder, supplied by VWR International Limited 
145 (Lutterworth, UK), HPLC-gradient grade acetonitrile, 35% v/v ammonium hydroxide solution 
146 and Analytical-Reagent grade dichloromethane, which were all purchased from Fischer 
147 Chemical (Loughborough, UK).  The materials required for aerosolisation, deposition and 
148 dissolution of FP were provided by Inhalation Sciences, Sweden.  For FP dissolution in rat IPL, 
149 female CD IGS (Sprague Dawley) rats were obtained from Charles River (Sulzfeld, Germany) 
150 and the necessary equipment were provided by Inhalation Sciences, Sweden.  
151
152 2.2 Preparation of calibration curve and validation of assay
153 Primary stock solutions of FP and FP-d5 were prepared by adding 1 mg of FP or FP-d5 into a 
154 10 mL volumetric flask and filled to the volume with pure acetonitrile, producing 100 µg/mL 
155 solutions, and stored at -20°C.  A 1 µg/mL FP working solution was prepared by the appropriate 
156 dilution of the stock with pure acetonitrile.  The calibration standards (156, 313, 625, 1250, 
157 2500, 5000 and 10,000 pg/mL) were prepared from serial dilution of the working solution with 
158 pure acetonitrile.  Method validation was conducted in terms of linearity, precision (intra-day 
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8159 and inter-day), accuracy, limit of detection and limit of quantification. Linearity was evaluated 
160 by plotting a calibration curve of mean peak area ratio of FP/FP-d5 (n=9) against the 
161 concentrations of 7 standards, using a weighted (1/x) linear regression model.  The coefficient 
162 of variation (%CV) was calculated across 3 calibration sets prepared on the same day for intra-
163 day precision.  For inter-day precision, another 3 fresh series of calibration standards prepared 
164 on days 2 and 3 were analysed.  Accuracy of the data was also evaluated across 9 determinants 
165 of each standard, ensuring it was within 15% of each standard concentration.  The limit of 
166 detection (LOD) and limit of quantification (LOQ) were calculated based on Equations. (1) 
167 and (2) respectively [19].
168 LOD = 3.3 x [SD/slope]                                                                                                        (1)
169 LOQ = 10 x [SD/slope]                                                                                                         (2)
170 Where SD is the standard deviation of the y estimate (peak area ratio) and slope is the gradient 
171 of the line.
172
173 2.3 Deposition and dissolution of FP aerosol in the DissolvIt system
174 The aerosolisation of Flixotide was carried out by connecting the Flixotide pMDI canister to 
175 the US Pharmacopeia Induction Port No 1 (standardised simulation of the throat) of the 
176 PreciseInhale aerosol system from Inhalation Sciences (Stockholm, Sweden) (Figure 1). The 
177 aerosol particles were deposited on 9 circular microscope glass cover slips, 13 mm in diameter 
178 and the dissolution of the deposited particles was investigated by interfacing the particles with 
179 the dissolution medium in the DissolvIt dissolution system from Inhalation Sciences, 
180 (Stockholm, Sweden)[16], thermostatted to 37°C.  Pre-warmed dissolution medium, 5.7 µL 
181 PEO, Survanta or SLF, was applied to the polycarbonate membrane (pore size 0.03 µm) of 
182 each DissolvIt dissolution chamber, with the perfusate buffer streaming on the other side.  The 
183 flow past perfusate consisted of 0.1 M phosphate buffer containing 4% w/v albumin solution, 
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9184 mixed using a magnetic stirrer.  The perfusate was de-gassed using helium to remove excess 
185 bubbles and streamed at a flow rate of 0.4 mL/min over a period of 4 h with samples collected 
186 by an automated fraction collector at 0, 3, 6, 9, 12, 15, 20, 25, 30, 40, 50, 60, 120 and 240 min.  
187
188 2.4 Dissolution of FP aerosol in rat isolated perfused lungs
189 Female rats with body weight 279 ± 20 g, were euthanized with phenobarbital sodium (100 
190 mg/kg, i.p.) and their whole lungs were maintained ex vivo as described in other reports [32,33].  
191 The lungs were placed in the artificial thoracic chamber.  They were ventilated with room air 
192 at 75 breaths/min by creating an alternating negative pressure (-0.2 to -0.8 kPa)3 inside the 
193 chamber, using an Ugo Basile model 7025 animal respirator (Varese, Italy), with a stroke 
194 volume of 6 mL, superimposed on a constant vacuum source connected to the chamber.  The 
195 tracheal air flow velocity and pressure inside the chamber were measured with a heated Hans 
196 Rudolph 8430 series pneumotachograph (Kansas City, USA) at 0-3 L/min and a differential 
197 pressure transducer from EMKA Technologies (Paris, France), respectively.  The physiological 
198 lung-function variables: tidal volume (Vt), dynamic lung compliance (Cdyn)[34] and lung 
199 conductance (Gaw), which is inversely proportional to lung resistance (RL)[34] were calculated 
200 from each breath in real time and logged by a data acquisition system using the EMKA 
201 Technologies software IOX v. 6.1a. The lungs were perfused via the pulmonary artery in a 
202 single-pass mode, at a constant hydrostatic pressure of approximately 12 cm H2O and the 
203 perfusate reservoir was continually overflowing into a recirculation drain pipe, in order to keep 
204 a constant liquid pressure head.  Throughout the experiments, the perfusate flow rate after the 
205 passage through the lungs (Qperf) was measured gravimetrically using a custom-made fraction 
206 collector with a balance. The perfusion medium consisted of Krebs-Henseleit buffer, 5.5 mM 
207 glucose, 12.6 mM HEPES and 4% w/v bovine serum albumin.  The temperature of the 
208 perfusate and the artificial thoracic chamber were maintained at 37°C.  The lungs were left to 
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209 stabilize for 30 min prior to aerosol exposures and only the lung preparations with stable 
210 baseline values for Vt, Cdyn, Gaw and Qperf during at least a 15-min period were used. The 
211 measured values were: Vt: 1.8 ± 0.2 mL, Cdyn: 6.6 ± 1.0 mL/kPa; Gaw: 279 ± 20 ml/s/kPa, and 
212 Qperf: 32 ± 2 mL/min (n=6). Administration of Flixotide aerosol to the IPL was carried out 
213 using the PreciseInhale system as described above, where the aerosol was delivered to the lungs 
214 by the active dosing system and the system automatically terminated the exposure when the 
215 inhaled target dose was reached.  The perfusate was sampled using an automatic fraction 
216 collector over a 2 h period from the start of the aerosol exposure with sampling intervals of 4.5, 
217 6, 7.5, 9, 12, 15, 30, 60 and 120 min.  After the end of the perfusion period, the lungs and 
218 trachea were harvested for analysis of the amount of FP retained in the tissues after the 
219 perfusion period to enable mass balance calculations.  The experiments were approved by a 
220 local ethical review board in Stockholm. 
221
222 2.5 Sample extraction
223 Samples were prepared for analysis following a new solid phase extraction method. Each 
224 sample, 325 µL, was loaded into a deep-well sample plate from Thermo-Scientific (Surrey, 
225 UK) followed by 50 µL of internal standard (0.1 µg/mL FP-D5).  Zinc sulphate 0.1 M, 300 µL, 
226 followed by 75 µL of 10% ammonium hydroxide were added and mixed using a multichannel 
227 pipette.  The SPE plate was placed on an orbital shaker for 30 min followed by centrifugation 
228 at 3700 rpm for 5 min.  The samples were then transferred to a pre-conditioned Evolute® 
229 Express ABN 10 mg SPE 96-well plate by Biotage (Uppsala, Sweden) and washed by applying 
230 low vacuum with 200 µL HPLC-grade water followed by 200 µL of 25% v/v methanol in 
231 water.  The analytes were eluted twice with 200 µL of pure acetonitrile, once with 100 µL 
232 dichloromethane then vacuum centrifuged to dryness.  Samples were reconstituted with 30 µL 
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233 of 55% v/v acetonitrile in water and sonicated rapidly for 10 min.  Finally, an aliquot of the 
234 sample (20 µL) was injected into the LC-MS/MS system.
235
236 2.6 FP quantification using LC-MS/MS
237 Quantification of FP was carried out by Waters® Xevo TQ tandem quadrupole mass 
238 spectrometer by Waters (Elstree, UK) equipped with an ESI interface, coupled with a Waters 
239 Acquity Ultra High Performance LC system (UPLC), equipped with a binary solvent delivery 
240 system.  Chromatographic separations were carried out on a Waters  Acquity UPLC BEH C18 
241 column 130Å, 1.7 µm, 2.1 x 50 mm.  The mobile phase was a mix of mobile phase A and 
242 mobile phase B, which were 0.1% ammonium hydroxide in water and 1:1 v/v acetonitrile in 
243 water, respectively.  The flow rate of the mobile phase was 0.2 mL/min with a 2 min gradient 
244 from 50% to 95% B.  Argon was used as the collision gas and the collision energy was set at 
245 12 V. The LC-MS/MS operations were controlled by the computer software, MassLynx 4.1 
246 and analyte quantification was performed with multiple reaction monitoring using the 
247 following transitions: m/z 501.4 > 313.1 for FP and m/z 506.4 > 313.1 for FP-d5.  
248
249 2.7 Data analysis.
250 For the validation process, peak integrations and data analysis were performed using the 
251 MassLynx 4.1 computer software.  The relationship between peak area ratio and FP 
252 concentration (pg/mL) was calculated using the LINEST function in Microsoft Excel.  Data 
253 was expressed as the mean ± standard deviation of replicate determinations, where n ≥ 3.  For 
254 the DissolvIt system, the FP transferred to the perfusate was expressed as a percent of the 
255 deposited amount on the glass slide.  For statistical analysis, One-Way ANOVA was applied 
256 to the data followed by Tukey POST-HOC analysis, using the IBM SPSS version 22 software.  
257 Data was identified as statistically significant when p ≤ 0.05.  
258
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259 2.8 Mechanistic modelling
260 2.8.1. Simulation of plasma concentration-time profiles of fluticasone
261 A mechanistic physiologically based pharmacokinetic (PBPK) model for predicting the fate of 
262 inhaled FP (as illustrated in Figure 2) was developed using Java (Version 1.8.0_111, Oracle, 
263 Redwood City, US). The integration of the system of ordinary differential equations was 
264 performed via the 8(5,3) Dormand-Prince integrator[35] as realized in the Apache Commons 
265 Math library Version 3.6.1 from Apache Software Foundation (Forest Hill, U.S.).  The model 
266 was adapted from that published by Boger et al.[31].  Briefly, the model was based on the 
267 respiratory physiology divided into three compartments; extra-thoracic, tracheobronchial 
268 (central lung) and alveolar (peripheral lung) region (Figure 2).  The particles deposited in the 
269 extra thoracic region were swallowed and transferred to gut, where they were subjected to 
270 systemic absorption, based on their bioavailable fraction (F).  Particles deposited in the central 
271 and peripheral lung regions were modelled for their dissolution in epithelial lung lining fluid, 
272 using input from the in vitro dissolution experiments in DissolvIt system.  The in vitro data 
273 were fitted to a Weibull function to extract the shape and time scale parameters that were then 
274 used to model the dissolution of particles in the model.  FP permeation in lung tissues and 
275 mucociliary clearance of particles deposited in the central lung were modelled as described by 
276 Boger et al.[31]  The central and peripheral lung areas were perfused by the bronchial blood 
277 flow (Q_central lung) and entire cardiac output (Q_cardiac output), respectively. Perfusion-
278 rate limited distribution was assumed to apply for all tissues. System-specific input parameters 
279 for central lung, peripheral lung, blood flows and volume of the tissue compartments are 
280 provided under supporting information (Tables S1 and S2).
281
282 For regional lung deposition modelling, the particle size distribution of the tested formulations 
283 was determined using next generation impactor (NGI), resulting in a discrete distribution of 
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284 seven particle sizes with corresponding mass fraction deposited (f0,….f6). Multiple-Path 
285 Particle Dosimetry model MPPD V2.11 2009 from Applied Research Associates Inc 
286 (Albuquerque, US) was used to calculate the regional deposition of particles from the tested 
287 formulations. A breathing pattern with 2 s inspiration, 1 s expiration, 10 s breath hold and a 
288 tidal volume of 625 mL was used[36]. The Yeh-Shum 5-lobe lung model was chosen for the 
289 calculations of regional deposition fraction[37].  The drug and formulation specific parameters 
290 for FP inhaled in the model are provided under supporting information (Table S3). 
291
292 2.8.2. Sensitivity analysis of dissolution kinetics
293 A sensitivity analysis of the pharmacokinetic parameters to the in vitro dissolution kinetics of 
294 FP was performed using the mechanistic PBPK model (described in section 2.7.1.). 
295 Hypothetical in vitro dissolution profiles of FP were created by means of numerical 
296 approximation with maximum cumulative percent dissolved fixed to mimic the cumulative 
297 percent of FP in SLF. The numerical approximations were selected in order to probe three 
298 different possible in vitro dissolution scenarios: a profile where release greatly exceeded that 
299 observed experimentally in SLF (case 1) and two profiles that are similar to SLF but initially 
300 more rapid (case 2) or slower (case 3).  The data was fitted to a Weibull function to extract the 
301 shape (b) and time scale (a) parameters of these profiles. The Weibull equation (Equation 3) 
302 was applied to describe the hypothetical dissolution curves and used as an input to the PBPK 
303 model. It describes the accumulated fraction of the drug (m) in solution at time t. The location 
304 parameter (Ti) is the lag time before the onset of the dissolution, and in all investigated cases 
305 was zero. 
𝑚 = 1 ― 𝑒𝑥𝑝[ ―(𝑡 ― 𝑇𝑖)𝑏𝑎 ] (3)
306
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307 3. Results
308
309 3.1 Extraction and quantification of fluticasone propionate using LC-MS/MS
310 As published methods for FP analysis[21-23] proved difficult to replicate with adequate 
311 reproducibility and sensitivity, a new SPE method for sample preparation was developed for 
312 use with LC-MS/MS for the assay of FP in bio-relevant media.  The methodology was easy to 
313 perform and the relationship between the mean peak area ratio of FP/FP-d5 and the 
314 concentration of FP in the samples was linear (R2 value=0.999) with inter-day and intra-day 
315 precision (CV) being < 20% (in according to ICH guidelines), except for 156 pg/mL.  The 
316 accuracy for all FP standard concentrations was within 85-115% (Figure 3).  The LOD and 
317 LOQ were 106 pg/mL and 312 pg/mL respectively.  Since the FP concentrations in all 
318 dissolution experiments fell within the upper range of the assay, the method was fit for purpose.
319
320 3.2 Dissolution of FP in DissolvIt and IPL
321 The penetration of FP, manifested as perfusate concentration, was higher at all time points 
322 when the dissolution medium was PEO or Survanta with lipid content lower than that of SLF 
323 (Figure 4), in good agreement with the theoretical models.  However, overall the influence of 
324 medium on FP dissolution was limited since the difference in the FP perfusate concentration 
325 values were not statistically significant (One-Way ANOVA, p>0.05) between dissolution in 
326 any of three lung fluids at most time points, except the difference in FP concentration for PEO 
327 and SLF at 20 min.  The FP concentration-time profile in perfusate was also similar between 
328 PEO and Survanta, both reaching a Cmax at approximately 20 min.  The cumulative percent of 
329 FP transferred into the perfusate over time in the DissolvIt system showed similar profiles in 
330 each dissolution medium reflecting the ranking observed in the perfusate concentrations, 
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331 whereas administration to the rat IPL resulted in concentrations of FP and cumulative % of FP 
332 in the perfusate that were significantly higher at nearly all time points (Fig 5).
333
334 3.3. In silico modelling of FP dissolution.
335 Pharmacokinetic parameters (Cmax, Tmax and AUC0-∞), calculated from the simulated plasma 
336 concentration time profiles for the different lung fluid simulants, predicted within two-folds 
337 the observed pharmacokinetic parameters of inhaled FP (1000 µg dose) administered via 
338 Flixotide Evohaler 250 μg strength inhaler[38] (Figure 6).  No significant difference was found 
339 between the clinically observed and simulated pharmacokinetic parameters when in vitro 
340 dissolution input from PEO and Survanta was used in the developed PBPK model. However, 
341 differences (p>0.05) in Cmax and AUC0-∞ compared to the clinical data were found when the 
342 slower in vitro dissolution of FP in SLF was modelled.  The AUC0-∞ predicted by the model 
343 for all three media were slightly underestimated owing to the underestimation of terminal time 
344 points of plasma concentration-time profile of inhaled FP suggesting that FP is retained for 
345 longer in the airways, which if incorporated into the model would improve the simulation.
346
347 To understand the sensitivity of the predicted PK parameters towards the dissolution profiles 
348 of FP, different hypothetical dissolution profiles were created (Figure 7).  In the cases where 
349 the dissolution-time curves differed from the SLF profile only in terms of faster or slower initial 
350 rate (cases two and three), a similar shape parameter described the exponential curves (b~1). 
351 Fitting of an immediate release type hypothetical dissolution profile (case one) resulted in a 
352 value describing a sigmoidal curve (b>>1).  Calculated values of AUC for the cases were 
353 similar to the values generated for SLF, which reflecting the fixing of the cumulative 
354 percentage of dissolved FP to 9.34% in 4 h.  Differences were observed in terms of Cmax and 
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355 Tmax with profiles when drug dissolution was faster/slower than in vitro dissolution profile of 
356 FP in SLF.  Dissolution profiles mimicking the faster dissolution rates (case one and case two) 
357 predicted higher values of Cmax (6- and 2-fold), and lower values of Tmax (6- and 4-folds) 
358 compared to the values observed in SLF. 
359
360 4. Discussion
361 The use of different dissolution media in the DissolvIt dissolution assay was investigated.  A 
362 PEO-based medium is used as the ‘standard’ solvent for the DissolvIt system and possesses a 
363 lipid content of 4 mg/mL, which was lower than that of SLF (5.4 mg/mL; Figure 4a).  Survanta 
364 is a lung surfactant extract concentrate and was diluted (1:5 with water) to normalise the lipid 
365 concentration to that of PEO.  PEO has no biological relevance beyond providing a viscosity 
366 that could be regarded as analogous to that provided by respiratory mucus in the airways[39].  
367 The slower appearance of FP in the perfusate when using SLF compared to PEO or Survanta 
368 may reflect slower dissolution or greater retention of FP as a result of the drug preferentially 
369 residing or becoming trapped within the more abundant lipid/lamellar structures in SLF, which 
370 also contains cholesterol.  Cholesterol can form tight nanodomain complexes with DPPC, 
371 stabilising DPPC in lipid structures in which FP can be solubilised and retained[40].  
372
373 Appearance of a low-soluble inhalant in perfusate or plasma is a serial process of dissolution 
374 in lung lining fluid followed by diffusion through the air-to-blood barrier. The second step is 
375 controlled by barrier thickness and lipid content and distribution within the barrier. While the 
376 mathematics of transport in such two-phase heterogeneous barriers was established decades 
377 ago[41, 424], the concept was later investigated for lipophilic toxicants in the airway lining 
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378 layer[43]. By adding a small amount of surfactant to an aqueous model of the airway lining 
379 layer, the penetration of lipophilic benzo(a)pyrene through the experimental barrier was greatly 
380 reduced[44]. Thus, a higher content of disperse lipids SLF would be expected to reduce 
381 penetration of lipophilic drugs.
382
383 Although the simulations in this study were based entirely on human parameters, including the 
384 ratio of central:peripheral aerosol deposition, the ex vivo rat IPL model was used as a 
385 comparator for experimentally-determined dissolution-permeation profiles.  The PreciseInhale 
386 system provides the advantage of a common delivery platform that can be used to deliver 
387 accurate dose and identical respirable aerosol fractions from the pMDI to the in vitro 
388 dissolution apparatus and ex vivo model.  The concentration of FP and cumulative proportion 
389 of FP in the perfusate was significantly higher at nearly all time points following administration 
390 to the rat IPL compared to DissolvIt.  The higher rate of absorptive clearance was attributed to 
391 the IPL possessing a comparatively rapid peripheral (alveolar) dissolution-permeation 
392 component in addition to slower central (airway) dissolution-permeation.  In contrast, the 
393 DissolvIt system is hypothesised to model better the dissolution and absorptive clearance 
394 mechanisms in the central airways.  In the central regions of the lungs, non-sink conditions 
395 may be expected as the dose is distributed over a smaller area compared to the alveolar region 
396 and dissolved FP molecules are required to diffuse across the 5-20 µm pseudostratified 
397 epithelium, compared to 1-2 µm in the alveoli of the lungs, to reach the perfusate[17].  The 
398 DissolvIt® system possesses an effective dissolution area of 0.95 cm2 and the penetration 
399 distance is approximately 60 µm.  Despite being an ex vivo non-human model, the IPL is an 
400 adaptable tool for teasing out the contributions of dissolution and permeation in different 
401 regions of the lungs to drug absorption and local exposure.  
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402
403 As FP exhibits dissolution rate-limited absorption from the lungs of humans[31,45], modelling 
404 was carried out to understand the sensitivity of simulated plasma concentration-time profiles 
405 of inhaled FP to dissolution profiles.  When faster dissolution rates compared to the values 
406 observed in SLF were modelled (Figure 7), the higher predicted higher values of Cmax and lower 
407 values of Tmax were obtained as a result of higher drug concentration in solution during the 
408 early stages of the dissolution process.  Where the initial rate of in vitro dissolution was lower 
409 than that in SLF, a lower Cmax and higher Tmax value were predicted.  This showed clearly the 
410 ability of the developed PBPK model to respond to the differences in the in vitro dissolution 
411 profiles and translate the differences to the respective PK parameters despite the rapid 
412 peripheral dissolution and absorption implied by the IPL studies being unaccounted.  These 
413 results illustrate how dissolution profiles can have significant impact on the PK parameters of 
414 a poorly soluble inhaled drug and demonstrate the application of biorelevant in vitro assays 
415 together with PBPK modelling.
416
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417 5. Conclusion
418 We report the development of experimental methods for performing biorelevant dissolution 
419 studies for orally inhaled products illustrated by a study into the impact of the dissolution of 
420 FP, an archetypal poorly soluble inhaled drug, on plasma pharmacokinetics when the drug was 
421 delivered using Flixotide.  The in silico model was able to translate the in vitro data for FP 
422 dissolution in the lungs into impacts on physiologically-relevant simulated plasma 
423 concentration-time profiles. This approach can lead to enhanced understanding regarding how 
424 dissolution processes of inhaled poorly soluble drugs may influence absorptive clearance from 
425 the lungs. 
426
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447
448
449 Figure 1. A schematic diagram of a) fluticasone propionate aerosolisation and 
450 particle deposition and b) the dissolution system
451
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462
463 Figure 2. A schematic diagram representing the whole body physiologically based 
464 pharmacokinetic (PBPK) model.
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486
487
488 Figure 3. Validation of the solid phase extraction and LC-MS/MS assay of fluticasone 
489 propionate (FP): a) Linearity of the mean peak area ratio vs concentration; b) FP 
490 concentration, precision and accuracy.  Data expressed as mean ± SD (n=9).
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491
492
493 Figure 4. a) Protein and lipid concentration in polyethylene oxide in phosphate buffer 
494 solution (PEO), simulated lung lining fluid (SLF) and Survanta® and b) Concentration 
495 of FP in the perfusate over time following dissolution in PEO, SLF and Survanta 
496 normalised to mass deposited on the glass cover slips. **Difference in FP 
497 concentration in PEO and SLF is statistically significant (One-Way ANOVA, p<0.05). 
498 Data expressed as mean ± SD (n=3).
499
500
501
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506
507 Figure 5. a) Concentration of FP in the perfusate over time following dissolution in 
508 polyethylene oxide in buffer solution (PEO), simulated lung lining fluid (SLF), 
509 Survanta and rat isolated perfused lung (IPL). *Difference in FP concentration in 
510 IPL and SLF is statistically significant (One Way ANOVA, p < 0.05). **Difference in 
511 FP concentration in IPL and the remaining three lung fluids, PEO, SLF and 
512 Survanta® is statistically significant (One Way ANOVA, p < 0.05) and b) Cumulative 
513 % of FP transferred into the perfusate over time, following its dissolution in PEO, 
514 SLF Survanta and IPL. Data expressed as mean ± SD (n=3).
515
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516
517
518 Figure 6. In-silico modelling. a) Simulated plasma concentration of FP over time, 
519 following its dissolution in polyethylene oxide in buffer solution (PEO), simulated 
520 lung lining fluid (SLF) and Survanta. b) Pharmacokinetic data of FP absorbed in 
521 plasma from healthy volunteers, after inhalation of FP pMDI (In-vivo) and of FP 
522 absorbed in perfusate, following its dissolution in PEO, SLF and Survanta. Data 
523 expressed as mean ± SD (n=3 or 9).
524
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536
537
538 Figure 7. Sensitivity testing using numerical approximation to derive three dissolution 
539 profiles that vary from the experimental observations for dissolution of fluticasone in 
540 SLF (observed): a profile where release greatly exceeded that observed 
541 experimentally in SLF (case 1) and two profiles that are similar to dissolution SLF 
542 but initially more rapid (case 2) or slower (case 3).
543
544
545
546 Table 1: Fitted Weibull shape factor (b) together with pharmacokinetic data of FP 
547 following its dissolution in SLF and artificial dissolution profiles (Cases 1-3); *n=3, 
548 **n=1
Parameter SLF* Case 1** Case 2** Case 3**
Weibull shape 
parameter
1.5285 ± 0.08 3.0204 1.1508 1.8716
Cmax (ug/L) 0.74 ± 0.05 4.61 1.44 0.53
Tmax (h) 3.01 ± 0.58 0.50 0.75 6.00
AUC0-∞ (ug/L h) 6.46 ± 0.08 6.92 6.87 6.04
549
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